logo
logo
Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc.

NASDAQ•RANI
CEO: Mr. Mir A. Imran
セクター: Healthcare
業種: Biotechnology
上場日: 2021-07-30
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
連絡先情報
2051 Ringwood Avenue, San Jose, CA, 95131, United States
408-457-3700
www.ranitherapeutics.com
時価総額
$97.81M
PER (TTM)
-1.7
34.6
配当利回り
--
52週高値
$3.87
52週安値
$0.39
52週レンジ
27%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.12-50.00%
直近4四半期の推移

フリーCF

-$5.06M-40.68%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Net loss attributable to RANI narrowed 20.2% to $5.4M for Q3 2025, reflecting improved operational efficiency compared to prior period.
Operating Expenses Under Control R&D expenses dropped 47.8% to $3.2M in Q3 2025 due to cost containment efforts, including temporary pause of certain programs.
Major Financing Closed October Company secured approximately $60.3M gross proceeds in October 2025 Private Placement, alleviating immediate going concern doubts.
Chugai Collaboration Revenue Stream New collaboration provides $10.0M upfront payment expected soon, plus potential milestones up to $180.0M and royalties.

リスク要因

Need for Future Capital Expect continued operating losses requiring substantial additional capital raises soon to fund platform development and clinical trials.
Collaboration Success Uncertainty Milestone and royalty payments depend on successful development, regulatory approval, and commercialization of the Chugai collaboration Product.
Nasdaq Listing Compliance History Recently regained compliance with Minimum Bid Price and MVLS requirements; future compliance is not guaranteed, risking delisting.
Global Trade Policy Risks International trade policies, tariffs, and geopolitical factors pose risks to supply chain complexity and manufacturing costs.

見通し

RaniPill HC Clinical Initiation Intends to initiate Phase 1 clinical testing for the high-capacity RaniPill HC device by the end of 2025.
RT-114 Phase 1 Trial Planned Plans to initiate a Phase 1 trial for RT-114, a GLP-1/GLP-2 agonist, by the end of 2025.
Stockholder Approval Sought Agreed to seek stockholder approval within 75 days for shares issuable upon exercise of Common Warrants from Private Placement.
Manufacturing Optimization Continues Will continue to scale and optimize automated manufacturing processes, requiring material future capital outlays and fixed costs.

同業比較

売上高 (TTM)

Innate Pharma S.A.IPHA
$36.93M
-61.2%
Sangamo Therapeutics, Inc.SGMO
$32.88M
-37.1%
Tonix Pharmaceuticals Holding Corp.TNXP
$10.30M
-8.8%

粗利益率 (最新四半期)

Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp
Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Cardiff Oncology, Inc.CRDF
100.0%
+5842.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CYBN$413.02M-2.0-54.5%15.9%
TNXP$203.46M-1.4-55.2%0.2%
MOLN$177.27M-2.2-51.0%1.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月30日
|
EPS:-$0.03
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.12-50.0%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.18-30.8%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月13日|
    売上高: $172.00K+0.0%
    |
    EPS: $-0.22-24.1%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月31日|
    売上高: $1.03M+0.0%
    |
    EPS: $-1.05+21.1%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.24-33.3%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.26-29.7%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.29-12.1%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月20日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.33-3.9%
    不明